ABSTRACT
ABSTRACT Introduction: Systemic lupus erythematosus (SLE) is a chronic disease that affects multiple systems and may include neurological and psychiatric events that could compromise treatment adherence and long-term outcomes in SLE. Objective: To evaluate treatment adherence in patients with diffuse neuropsychiatric disorders associated with SLE. Methods: A cross-sectional descriptive study was conducted. Treatment adherence was eval uated with the Morisky Medication Adherence Scale (MMAS-8) in patients with diffuse neuropsychiatric disorders associated with SLE (cognitive impairment, psychosis, mood disorders, and anxiety). Results: A total of 60 patients with neuropsychiatric disorders associated with SLE were included. Thirteen patients (21.6%) had high adherence, 9 (15%) had medium adherence, and 38 patients (63.3%) had low treatment adherence. Conclusion: This study has identified that almost two-thirds of the participants (63.3%) had low treatment adherence.
RESUMEN Introducción: El lupus eritematoso sistémico (LES) es una enfermedad crónica que afecta a múltiples sistemas, entre ellos el sistema nervioso, con eventos neurológicos y psiquiátricos que podrían influir en la adherencia al tratamiento y los resultados a largo plazo de la enfermedad. Objetivo: Evaluar la adherencia al tratamiento de los pacientes con trastornos neuropsiquiátricos difusos asociados con el LES. Metodología: Se llevó a cabo un estudio descriptivo transversal que evaluó el grado de adhe rencia al tratamiento con el test de Morisky en pacientes con trastornos neuropsiquiátricos difusos asociados con LES (alteración cognitiva, psicosis, trastornos del ánimo y ansiedad). Resultados: Se incluyó a 60 pacientes con trastornos neuropsiquiátricos difusos asociados con LES, de los cuales 13 (21,6%) tuvieron adherencia alta, 9 (15%) adherencia media y 38 (63,3%) presentaron baja adherencia al tratamiento. Conclusión: En este estudio se identificó que más de la mitad de los participantes (63,3%) presentaron baja adherencia al tratamiento.
Subject(s)
Humans , Adolescent , Adult , Behavioral Sciences , Skin and Connective Tissue Diseases , Connective Tissue Diseases , Behavioral Disciplines and Activities , Neuropsychiatry , Lupus Erythematosus, SystemicABSTRACT
Currently, the evaluation of mental disorders in patients with Systemic lupus erythematosus (SLE) is essential in the management of the illness because of their impact in morbimortality. The main purpose of this study was to determine the prevalence of mental disorders in a group of patients with SLE in a tertiary referral hospital in Quito-Ecuador. The main diffuse central nervous system psychiatric syndromes in SLE (psychosis, anxiety and mood disorders) and cognitive dysfunction were evaluated with the MINI International Neuropsychiatric Interview and the Montreal scale, respectively. This was a descriptive, cross-sectional study which included patients 15 years and older diagnosed with SLE in a tertiary referral hospital in Quito, Ecuador. 85 patients diagnosed with SLE attending the internal medicine outpatient clinic during October 2017-May 2018 were included. A bivariate analysis of possible associations between these mental disorders with corticosteroid use, antiphospholipid syndrome (APS), and quality of life was also studied. Eighty-five patients, with an average age of 34.12 ± 11.5 years were included, of which 94% were females. 71% of participants (60 patients) had at least one mental disorder evaluated in this study. The most frequent was cognitive impairment (n = 43, 51%) followed by anxiety disorders (n = 35, 41%), mood disorders (n = 34, 40%) and psychosis (n = 1; 1%). 38% presented mild cognitive impairment and 13% had moderate cognitive impairment. Memory and visuospatial/executive function were the most affected domains in the cognitive assessment. 38% of participants were previously diagnosed with antiphospholipid syndrome, of which 78% had a mental disorder (OR = 1.83, p = 0.2). Most patients (n = 84; 99%) were treated with corticosteroids, of these, 59 patients presented a mental disorder (OR = 0.9, p = 0.8). Associations with APS or corticosteroid use were not statistically significant. However, the multivariate regression suggests an association between presence of mental disease and quality of life. There were statistically significant alterations in anxiety/depression and pain. There is a high prevalence of neuropsychiatric syndromes in this cohort of patients. Almost ¾ of our cohort had at least one mental disorder, the most common was cognitive impairment.